2024
ALL-438 Minimal Residual Disease–Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Receiving First-Line Therapy
Ashaye A, Chalandon Y, Boissel N, Fazioli K, Wang B, Aldoss I, Huang F, Leonard J, Szabo N, McCloskey C, Nair S, Dalal M, Hennessy M, Yeh T, Martinelli G, Badar T, Kantarjian H, Ribera J, Jabbour E. ALL-438 Minimal Residual Disease–Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Receiving First-Line Therapy. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s270-s271. DOI: 10.1016/s2152-2650(24)01111-x.Peer-Reviewed Original ResearchMinimal residual diseasePh+ acute lymphoblastic leukemiaAcute lymphoblastic leukemiaMRD-negative CRFirst-line therapyLong-term EFSIndividual patient dataComplete remissionFirst-lineMRD analysisLymphoblastic leukemiaPrognostic indicatorAdult patientsPrognostic indicators of long-term survivalDiagnosed Ph+ ALLPhiladelphia chromosome-positive acute lymphoblastic leukemiaMinimal residual disease levelsMinimal residual disease statusMRD-negative complete remissionIndicators of long-term survivalIndividual patient data analysisAchievement of CRStudy-level meta-analysisKaplan-Meier methodLog-rank test
2019
Impact of Insurance Status on Survival Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL): A Single Center Experience
Krakora R, Shih W, Popli P, Gorshein E, Salaru G, David K, Bannerji R. Impact of Insurance Status on Survival Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL): A Single Center Experience. Blood 2019, 134: 5071. DOI: 10.1182/blood-2019-129390.Peer-Reviewed Original ResearchProgression-free survivalAllogeneic stem cell transplantAcute lymphoblastic leukemiaTime of diagnosisAchievement of CRBetter overall survivalOverall survivalComplete remissionInsurance statusAcute myeloblastic leukemiaSurvival outcomesLymphoblastic leukemiaRegeneron PharmaceuticalsHealth insuranceSurvival rateSingle comprehensive cancer centerBetter progression-free survivalWorse progression-free survivalProportional hazards regression methodsPhiladelphia chromosome statusSingle-center experienceRetrospective chart reviewStem cell transplantComprehensive cancer centerLack of insurance
2015
Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL
Sethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N. Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL. Blood 2015, 126: 1441. DOI: 10.1182/blood.v126.23.1441.1441.Peer-Reviewed Original ResearchNodular sclerosis Hodgkin lymphomaProgression-free survivalOutcomes of patientsAdvanced stage diseaseOverall survivalComplete responseHodgkin's lymphomaB symptomsStage diseaseSV groupAchievement of CRInferior progression-free survivalMedian progression-free survivalHodgkin/Reed-Sternberg cellsInstitutional IRB approvalMedian overall survivalStandard ABVD chemotherapyStandard salvage regimensHigh-dose therapyKaplan-Meier methodOnly independent predictorStem cell transplantStage of diseaseCompletion of treatmentNew immunomodulatory agents
2008
Early Interim FDG-PET Scan Predicts Outcome in Non-Bulky Limited Stage Hodgkin Lymphoma, but may Not Guide Use of Consolidative Radiotherapy.
Barnes J, LaCasce A, Toomey C, Hochberg E, Lee A, Canellos G, Abramson J. Early Interim FDG-PET Scan Predicts Outcome in Non-Bulky Limited Stage Hodgkin Lymphoma, but may Not Guide Use of Consolidative Radiotherapy. Blood 2008, 112: 1453. DOI: 10.1182/blood.v112.11.1453.1453.Peer-Reviewed Original ResearchInterim PET scanNegative interim PET scanPositive interim PETConsolidative radiotherapyPrimary treatment failureStage Hodgkin lymphomaLimited stage Hodgkin lymphomaEnd of therapyTreatment failureInterim PETPET scansOverall survivalHodgkin's lymphomaComplete remissionCR patientsLimited-stage Hodgkin lymphomaAchievement of CRComplete response rateCompletion of chemotherapyCycles of chemotherapyInterim FDG-PETLimited stage diseaseLimited stage patientsNegative interim PETAnthracycline-based chemotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply